Sep 2026· Journal of Medicinal Chemistry· Vol 69 19, pp.
21919-21936
· 0 citations· 45 references
Medicine
TL;DR
CRAFT is a reaction-aware molecular optimization framework that integrates Monte Carlo Tree Search (MCTS) with a multimodal strategy network and explicitly encodes two-dimensional molecular topology and atom-level reaction roles, enabling chemically feasible transformations during multi-step optimization.
Abstract
Ensuring synthetic accessibility remains a major challenge in de novo drug design, as generative models can produce high-scoring molecules that are difficult to synthesize. To address this issue, we propose CRAFT, a reaction-aware molecular optimization framework that integrates Monte Carlo Tree Search (MCTS) with a multimodal strategy network. Unlike sequence-only baselines, CRAFT explicitly encodes two-dimensional molecular topology and atom-level reaction roles, enabling chemically feasible transformations during multi-step optimization. Comprehensive evaluations on DRD2, AKT1, and CXCR4 demonstrate that CRAFT consistently outperforms state-of-the-art methods, generating more high-scoring candidates while improving reaction-constrained synthetic accessibility and molecular diversity. CRAFT also rediscovers scaffolds homologous to known active ligands and identifies novel chemical entities beyond the training distribution, as supported by molecular docking simulations. Moreover, the model provides transparent forward-synthesis pathways for generated candidates, helping bridge in silico molecular design and practical synthesis.
The results show that integrating synthesizability prediction into physics-based GAL workflows enables the efficient design of compounds that are at once chemically diverse as well as predicted to be strong binders and synthetically tractable, demonstrating efficient and practical computational drug design.
Marco Klähn, Hannes H. Loeffler, S. Wan et al.· Journal of Chemical Theory a...· 0 citations
Designing target-specific bioactive molecules with actionable synthesis routes for the human proteome holds enormous potential for expanding therapeutic discovery, but remains a challenge. Existing target-aware generative models often depend on protein structures and generate molecules before assessing synthetic feasib...
Abstract Motivation Designing molecules with predefined properties remains a critical yet challenging task in drug discovery. Recent advances in deep learning have demonstrated strong potential in accelerating the identification of novel compounds with desired properties and activities. However, the implementation and...
PGFS++ is introduced, a synthesis-aware reinforcement learning framework for input-specific molecular improvement that improves target properties while preserving high output diversity, and experiments show that PGFS++ improves target properties while preserving high output diversity.
Bo-Qi Zhang, G. James, S. Gottipati et al.· 0 citations
LDDM (Large Drug Discovery Model) is introduced, a generative framework that supports a range of drug discovery tasks, including constrained and unconstrained docking, fragment linking and growing, and de novo design, and a programmable design algorithm that enables accurate design of synthetically accessible compounds...
Ilia Igashov, Arne Schneuing, Adrian W. Dobbelstein et al.· bioRxiv· 0 citations
A comprehensive evaluation of molecule generation models for de novo drug design, covering 82 methods across five deep generative frameworks, including recurrent neural network (RNN)- and transformer-based models, variational autoencoders (VAEs), generative adversarial networks (GANs), flow-based models, and diffusion...
Xin-Rui Xu, Xue-Er Wang, Dan Luo et al.· Journal of Chemical Informat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.